|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 05, 2016 ) Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:
Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.
Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.
Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the bodys ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=685165
Market analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
New report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Eli Lilly and Company
Novo Nordisk A/S
Sanofi SA
Other prominent vendors
Adocia
Astellas Pharma
AstraZeneca
Baxalta
BHV Pharma
Biocon
Biodel
Boehringer Ingelheim
CureDM
Dance Biopharm
Diamyd Therapeutics AB
Diasome Pharmaceuticals
DiaVac
Exsulin
Gan & Lee Pharmaceuticals
Generex Biotechnology
GlaxoSmithKline
ILTOO Pharma
Intrexon
Islet Sciences
Kamada
Kotobuki Pharmaceutical
Lexicon Pharmaceuticals
Living Cell Technologie
MacroGenics
MannKind Pharmaceuticals
Merck
Merrion Pharmaceutical
Oramed Pharmaceuticals
Osiris Therapeutics
Perle Biosciences
Pfizer
REGiMMUNE
Strongbridge Biopharma
Toleranzia
Tolerio
Xeris Pharmaceuticals
XOMA
Market driver
Increase in prevalence of type 1 diabetes
For a full, detailed list, view our report
Market challenge
Poor storage conditions and distribution policies for insulin
For a full, detailed list, view our report
Market trend
Awareness programs and initiatives
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Browse Detail Report With TOC @ http://www.researchmoz.us/global-type-1-diabetes-market-2016-2020-report.html
Table Of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Key buying criteria
PART 05: Disease overview
Introduction
Risk factors
Diagnosis
Management
Epidemiology
Economic burden
PART 06: Insulin: An overview
Product portfolio
Global human insulin market
PART 07: Pipeline analysis
Faster-acting insulin aspart (NN1218)
Farxiga/Forxiga
SAR342434
NN9211
LY2605541
Sotagliflozin
MK-1293
PRL001
Otelixizumab
PART 08: Reimbursement scenario in US
PART 09: Market landscape
Global diabetes drugs market
Global type 1 diabetes drugs market
Five forces analysis
PART 10: Market segmentation by drug class
Insulin
Others
PART 11: Geographical segmentation
Type 1 diabetes drugs market in Americas
Type 1 diabetes drugs market in EMEA
Type 1 diabetes drugs market in APAC
PART 12: Market drivers
Increase in prevalence of type 1 diabetes
Advances in insulin delivery technology
Rise in price of insulin drugs
Stringent regulatory conditions for biosimilar drugs
Promising drug pipeline
PART 13: Impact of drivers
PART 14: Market challenges
Side effects of current therapies
Fierce market competition
Poor storage conditions and distribution policies for insulin
Gap in nation-level diabetes management plans
Rising concerns in scientific community
PART 15: Impact of drivers and challenges
PART 16: Market trends
Development of drugs with novel mechanisms
Awareness programs and initiatives
Focus on emerging markets
Increase in academia-industry collaboration
PART 17: Vendor landscape
Competitive scenario
Market analysis 2015
Novo Nordisk
Sanofi
Eli Lilly
Other prominent vendors
PART 18: Appendix
List of abbreviations
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=685165
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Browse Our Latest Press Releases @ http://www.researchmoz.us/pressrelease
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
